Log In
Print this Print this

AR101 (formerly ARC001, Peanut Allergy Oral Immunotherapy (OIT))

  Manage Alerts
Collapse Summary General Information
Company Aimmune Therapeutics Inc.
DescriptionStandardized complex mixture of 13 naturally occurring peanut proteins
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase III
Standard IndicationAllergy
Indication DetailsTreat peanut allergies in patients ages 4-17; Treat peanut allergy
Regulatory Designation U.S. - Breakthrough Therapy (Treat peanut allergies in patients ages 4-17);
U.S. - Fast Track (Treat peanut allergy);
U.S. - Fast Track (Treat peanut allergies in patients ages 4-17)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today